Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low-Risk Papillary Thyroid Cancer

James X. Wu*, Catherine E. Beni, Kyle A. Zanocco, Cord Sturgeon, Michael W. Yeh

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Patients with low-risk papillary thyroid cancer (PTC) who demonstrate an excellent response to initial therapy have a 2% recurrence rate and 100% disease-specific survival within 10 years. Thus, annual surveillance may be excessive. We hypothesized that less frequent postoperative surveillance in these patients is cost effective. Methods: A Markov discrete time state transition model was created to compare postoperative surveillance tapered to 3-year intervals after 5 years of annual surveillance versus conventional annual surveillance in low-risk PTC patients with negative neck ultrasound and stimulated thyroglobulin less than 2 ng/mL 1 year postoperatively. Outcome probabilities, utilities, and costs were determined via literature review, the Medicare Physician Fee Schedule, and Healthcare Cost and Utilization Project data. Sensitivity analyses were performed to assess areas of uncertainty. Results: The cost of annual surveillance was $5,239 per patient and yielded 22.49 quality-adjusted life-years (QALYs). The 3-year strategy cost $2,601 less, but also yielded 0.01 less QALYs. Thus, the incremental cost per QALY of annual surveillance was $260,100. Probabilistic sensitivity analysis demonstrated that less frequent surveillance was more cost effective in 99.98% of 10,000 simulated patients. One-way sensitivity analysis revealed that annual surveillance would be cost effective if the total cost of neck ultrasound could be reduced to $23 or less. Conclusion: Extending postoperative surveillance to 3-year intervals after 5 years of annual surveillance in patients with low-risk PTC with excellent response to therapy is more cost effective than annual surveillance.

Original languageEnglish (US)
Pages (from-to)797-803
Number of pages7
JournalThyroid
Volume25
Issue number7
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cost-Benefit Analysis
Costs and Cost Analysis
Quality-Adjusted Life Years
Neck
Fee Schedules
Papillary Thyroid cancer
Thyroglobulin
Medicare
Health Care Costs
Uncertainty
Physicians
Recurrence
Survival
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Wu, James X. ; Beni, Catherine E. ; Zanocco, Kyle A. ; Sturgeon, Cord ; Yeh, Michael W. / Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low-Risk Papillary Thyroid Cancer. In: Thyroid. 2015 ; Vol. 25, No. 7. pp. 797-803.
@article{fd0102e7979c4f61a03c65806cecc194,
title = "Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low-Risk Papillary Thyroid Cancer",
abstract = "Background: Patients with low-risk papillary thyroid cancer (PTC) who demonstrate an excellent response to initial therapy have a 2{\%} recurrence rate and 100{\%} disease-specific survival within 10 years. Thus, annual surveillance may be excessive. We hypothesized that less frequent postoperative surveillance in these patients is cost effective. Methods: A Markov discrete time state transition model was created to compare postoperative surveillance tapered to 3-year intervals after 5 years of annual surveillance versus conventional annual surveillance in low-risk PTC patients with negative neck ultrasound and stimulated thyroglobulin less than 2 ng/mL 1 year postoperatively. Outcome probabilities, utilities, and costs were determined via literature review, the Medicare Physician Fee Schedule, and Healthcare Cost and Utilization Project data. Sensitivity analyses were performed to assess areas of uncertainty. Results: The cost of annual surveillance was $5,239 per patient and yielded 22.49 quality-adjusted life-years (QALYs). The 3-year strategy cost $2,601 less, but also yielded 0.01 less QALYs. Thus, the incremental cost per QALY of annual surveillance was $260,100. Probabilistic sensitivity analysis demonstrated that less frequent surveillance was more cost effective in 99.98{\%} of 10,000 simulated patients. One-way sensitivity analysis revealed that annual surveillance would be cost effective if the total cost of neck ultrasound could be reduced to $23 or less. Conclusion: Extending postoperative surveillance to 3-year intervals after 5 years of annual surveillance in patients with low-risk PTC with excellent response to therapy is more cost effective than annual surveillance.",
author = "Wu, {James X.} and Beni, {Catherine E.} and Zanocco, {Kyle A.} and Cord Sturgeon and Yeh, {Michael W.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1089/thy.2014.0617",
language = "English (US)",
volume = "25",
pages = "797--803",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low-Risk Papillary Thyroid Cancer. / Wu, James X.; Beni, Catherine E.; Zanocco, Kyle A.; Sturgeon, Cord; Yeh, Michael W.

In: Thyroid, Vol. 25, No. 7, 01.01.2015, p. 797-803.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low-Risk Papillary Thyroid Cancer

AU - Wu, James X.

AU - Beni, Catherine E.

AU - Zanocco, Kyle A.

AU - Sturgeon, Cord

AU - Yeh, Michael W.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Patients with low-risk papillary thyroid cancer (PTC) who demonstrate an excellent response to initial therapy have a 2% recurrence rate and 100% disease-specific survival within 10 years. Thus, annual surveillance may be excessive. We hypothesized that less frequent postoperative surveillance in these patients is cost effective. Methods: A Markov discrete time state transition model was created to compare postoperative surveillance tapered to 3-year intervals after 5 years of annual surveillance versus conventional annual surveillance in low-risk PTC patients with negative neck ultrasound and stimulated thyroglobulin less than 2 ng/mL 1 year postoperatively. Outcome probabilities, utilities, and costs were determined via literature review, the Medicare Physician Fee Schedule, and Healthcare Cost and Utilization Project data. Sensitivity analyses were performed to assess areas of uncertainty. Results: The cost of annual surveillance was $5,239 per patient and yielded 22.49 quality-adjusted life-years (QALYs). The 3-year strategy cost $2,601 less, but also yielded 0.01 less QALYs. Thus, the incremental cost per QALY of annual surveillance was $260,100. Probabilistic sensitivity analysis demonstrated that less frequent surveillance was more cost effective in 99.98% of 10,000 simulated patients. One-way sensitivity analysis revealed that annual surveillance would be cost effective if the total cost of neck ultrasound could be reduced to $23 or less. Conclusion: Extending postoperative surveillance to 3-year intervals after 5 years of annual surveillance in patients with low-risk PTC with excellent response to therapy is more cost effective than annual surveillance.

AB - Background: Patients with low-risk papillary thyroid cancer (PTC) who demonstrate an excellent response to initial therapy have a 2% recurrence rate and 100% disease-specific survival within 10 years. Thus, annual surveillance may be excessive. We hypothesized that less frequent postoperative surveillance in these patients is cost effective. Methods: A Markov discrete time state transition model was created to compare postoperative surveillance tapered to 3-year intervals after 5 years of annual surveillance versus conventional annual surveillance in low-risk PTC patients with negative neck ultrasound and stimulated thyroglobulin less than 2 ng/mL 1 year postoperatively. Outcome probabilities, utilities, and costs were determined via literature review, the Medicare Physician Fee Schedule, and Healthcare Cost and Utilization Project data. Sensitivity analyses were performed to assess areas of uncertainty. Results: The cost of annual surveillance was $5,239 per patient and yielded 22.49 quality-adjusted life-years (QALYs). The 3-year strategy cost $2,601 less, but also yielded 0.01 less QALYs. Thus, the incremental cost per QALY of annual surveillance was $260,100. Probabilistic sensitivity analysis demonstrated that less frequent surveillance was more cost effective in 99.98% of 10,000 simulated patients. One-way sensitivity analysis revealed that annual surveillance would be cost effective if the total cost of neck ultrasound could be reduced to $23 or less. Conclusion: Extending postoperative surveillance to 3-year intervals after 5 years of annual surveillance in patients with low-risk PTC with excellent response to therapy is more cost effective than annual surveillance.

UR - http://www.scopus.com/inward/record.url?scp=84936946316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936946316&partnerID=8YFLogxK

U2 - 10.1089/thy.2014.0617

DO - 10.1089/thy.2014.0617

M3 - Article

VL - 25

SP - 797

EP - 803

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 7

ER -